Improved Prostate Cancer Detection Using Combined Ultrasound and Photoacoustic Im

使用超声波和光声成像相结合改进前列腺癌检测

基本信息

  • 批准号:
    8569337
  • 负责人:
  • 金额:
    $ 17.07万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-07-08 至 2015-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Prostate cancer is the only malignancy diagnosed by non-lesion directed systematic biopsy. Nearly 800,000 transrectal ultrasound guided (TRUS) biopsy procedures will be performed in the United States this year resulting in the diagnosis of over 200,000 cases of prostate cancer. Despite the large number of biopsies performed, current prostate biopsy schemes miss approximately 15-25% of incident cancers. Accurate prostate imaging with reliable imaging characteristics could significantly reduce unnecessary biopsies, improve diagnostic accuracy and be used to monitor tumor size or characteristics for patients on active surveillance. Photoacoustic imaging (PAI) is an emerging optical (non-ionizing) imaging technique that can provide high optical contrast images with the high spatial and temporal resolution of ultrasound. PAI is capable of producing an in-vivo three-dimensional image with higher spatial resolution (up to 500 ¿m at tissue penetration depth of about 5 cm) than existing optical imaging modalities using photoacoustic effect (transformation of light to ultrasound). Endogenous photoacoustic signal is primarily produced from hemoglobin, making the technique well suited for imaging vascularized tissue, such as tumors. In order to provide a clinical grade device we have combined our recently improved photoacoustic detection technology, utilizing capacitive micromachined ultrasound transducer (CMUT) arrays for highly sensitive deep tissue imaging, with a TRUS platform. The goal of this proposal is to test combined transrectal ultrasound and photoacoustic (TRUSPA) imaging for guided prostate biopsy. To achieve this, the TRUSPA device will first be tested and optimized using prostate mimicking phantoms and surgically removed whole prostates with known prostate tumors. Following device validation, we will conduct a pilot test of the TRUSPA instrument in patients undergoing prostate cancer biopsy with and without the FDA approved injectable contrast agent indocyanine green (ICG). We hypothesize that the TRUSPA imaging device, with well-defined image metrics derived from initial testing, will accurately identify potential lesions for biopsy compared to traditional ultrasound guided biopsy and that the use of ICG dye will further enhance this effect.
描述(由申请人提供):前列腺癌是唯一通过非病变定向系统活检诊断的恶性肿瘤。今年,美国将进行近80万例经直肠超声引导(TRUS)活检手术,诊断出超过20万例前列腺癌。尽管进行了大量的活检,但目前的前列腺活检方案错过了大约15-25%的癌症事件。具有可靠成像特征的准确前列腺成像可以显著减少不必要的活检,提高诊断准确性,并用于监测主动监测患者的肿瘤大小或特征。光声成像(派)是一种新兴的光学(非电离)成像技术,可以提供具有超声高空间和时间分辨率的高光学对比度图像。派能够产生具有比现有的使用光声效应(光到超声的转换)的光学成像模式更高的空间分辨率(在约5 cm的组织穿透深度处高达500 μ m)的体内三维图像。内源性光声信号主要由血红蛋白产生,使得该技术非常适合于对血管化组织(诸如肿瘤)进行成像。为了提供临床级设备,我们将最近改进的光声检测技术与TRUS平台结合起来,该技术利用电容式微机械超声换能器(CMUT)阵列进行高灵敏度深度组织成像。本提案的目标是测试经直肠超声和光声(TRUSPA)联合成像用于引导前列腺活检。为了实现这一目标,TRUSPA设备将首先使用前列腺模拟体模进行测试和优化,并通过手术切除具有已知前列腺肿瘤的整个前列腺。器械确认后,我们将在接受前列腺癌活检的患者中对TRUSPA仪器进行试点测试,使用和不使用FDA批准的注射造影剂吲哚菁绿色(ICG)。我们假设TRUSPA成像设备具有来自初始测试的定义明确的图像指标,与传统的超声引导活检相比,将准确识别活检的潜在病变,并且使用ICG染料将进一步增强这种效果。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SANJIV S GAMBHIR其他文献

SANJIV S GAMBHIR的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SANJIV S GAMBHIR', 18)}}的其他基金

World Molecular Imaging Congress 2017: IMAGinING the Future: from Molecules to Medicine
2017 年世界分子影像大会:想象未来:从分子到医学
  • 批准号:
    9398016
  • 财政年份:
    2017
  • 资助金额:
    $ 17.07万
  • 项目类别:
Nanoparticle-Based Triple Modality Imaging and Photothermal Therapy of Brain Tumors
基于纳米颗粒的脑肿瘤三模态成像和光热疗法
  • 批准号:
    9092358
  • 财政年份:
    2016
  • 资助金额:
    $ 17.07万
  • 项目类别:
Nanoparticle-Based Triple Modality Imaging and Photothermal Therapy of Brain Tumors
基于纳米粒子的脑肿瘤三模态成像和光热疗法
  • 批准号:
    9766199
  • 财政年份:
    2016
  • 资助金额:
    $ 17.07万
  • 项目类别:
Optimization of an activatable photoacoustic agent to image thyroid cancer
优化可激活光声剂对甲状腺癌进行成像
  • 批准号:
    9223698
  • 财政年份:
    2015
  • 资助金额:
    $ 17.07万
  • 项目类别:
Developmental Program
发展计划
  • 批准号:
    8961578
  • 财政年份:
    2015
  • 资助金额:
    $ 17.07万
  • 项目类别:
Optimization of an activatable photoacoustic agent to image thyroid cancer
优化可激活光声剂对甲状腺癌进行成像
  • 批准号:
    9060321
  • 财政年份:
    2015
  • 资助金额:
    $ 17.07万
  • 项目类别:
Center for Cancer Nanotechnology Excellence for Translational Diagnostics (CCNE-TD)
转化诊断癌症纳米技术卓越中心 (CCNE-TD)
  • 批准号:
    9324940
  • 财政年份:
    2015
  • 资助金额:
    $ 17.07万
  • 项目类别:
Vevo LAZR Photoacoustic and Ultrasound Imaging System
Vevo LAZR 光声和超声成像系统
  • 批准号:
    8447766
  • 财政年份:
    2013
  • 资助金额:
    $ 17.07万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    7983248
  • 财政年份:
    2010
  • 资助金额:
    $ 17.07万
  • 项目类别:
Center for Cancer Nanotechnology Excellence and Translation (CCNE-T)
癌症纳米技术卓越与转化中心 (CCNE-T)
  • 批准号:
    8540368
  • 财政年份:
    2010
  • 资助金额:
    $ 17.07万
  • 项目类别:

相似海外基金

卵巣癌/子宮体癌における薬剤感受性メチル化診断キットの開発とLiquid Biopsyへの応用
卵巢癌/子宫内膜癌药物敏感甲基化诊断试剂盒的研制及其在液体活检中的应用
  • 批准号:
    24K02584
  • 财政年份:
    2024
  • 资助金额:
    $ 17.07万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
グリオーマのliquid biopsyによるメチル化網羅的解析とprecision medicineへの応用
胶质瘤液体活检甲基化综合分析及其在精准医疗中的应用
  • 批准号:
    24K12271
  • 财政年份:
    2024
  • 资助金额:
    $ 17.07万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Liquid biopsyを用いた炎症性腸疾患の早期診断法開発
液体活检炎症性肠病早期诊断方法的开发
  • 批准号:
    24K10595
  • 财政年份:
    2024
  • 资助金额:
    $ 17.07万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
精神的長期ストレス児童の口腔細菌叢と唾液成分の解析:唾液 liquid biopsyを目指して
长期精神应激儿童口腔菌群和唾液成分分析:唾液液体活检
  • 批准号:
    24K13206
  • 财政年份:
    2024
  • 资助金额:
    $ 17.07万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
MONALISA: A SIOPEN pragmatic clinical trial to MOnitor NeuroblastomA relapse with LIquid biopsy Sensitive Analysis
MONALISA:一项 SIOPEN 实用临床试验,通过液体活检监测神经母细胞瘤复发 敏感性分析
  • 批准号:
    10103126
  • 财政年份:
    2024
  • 资助金额:
    $ 17.07万
  • 项目类别:
    EU-Funded
A SIOPEN pragmatic clinical trial to MOnitor NeuroblastomA relapse with LIquid biopsy Sensitive Analysis (MONALISA)
SIOPEN 通过液体活检敏感性分析 (MONALISA) 监测神经母细胞瘤复发的实用临床试验
  • 批准号:
    10110442
  • 财政年份:
    2024
  • 资助金额:
    $ 17.07万
  • 项目类别:
    EU-Funded
Mutated human oncogene recombinant nucleosomes as reference materials for liquid biopsy
突变人癌基因重组核小体作为液体活检参考材料
  • 批准号:
    10090714
  • 财政年份:
    2024
  • 资助金额:
    $ 17.07万
  • 项目类别:
    Collaborative R&D
肝細胞癌における術中門脈血を用いたliquid biopsyの検討
肝细胞癌术中门静脉血液体活检检查
  • 批准号:
    24K19404
  • 财政年份:
    2024
  • 资助金额:
    $ 17.07万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Genetic diagnosis of vascular malformations by liquid biopsy and its application to precision medicine
液体活检对血管畸形的基因诊断及其在精准医疗中的应用
  • 批准号:
    23K09072
  • 财政年份:
    2023
  • 资助金额:
    $ 17.07万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Breath biopsy technology targeting for volatile oxidized lipids
针对挥发性氧化脂质的呼吸活检技术
  • 批准号:
    23K06080
  • 财政年份:
    2023
  • 资助金额:
    $ 17.07万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了